Baricitinib

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alopecia Areata

Conditions

Alopecia Areata

Trial Timeline

Jan 23, 2025 → Dec 31, 2026

NCT ID

NCT06797310

About Baricitinib

Baricitinib is a phase 2 stage product being developed by Eli Lilly for Alopecia Areata. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06797310. Target conditions include Alopecia Areata.

What happened to similar drugs?

1 of 20 similar drugs in Alopecia Areata were approved

Approved (1) Terminated (0) Active (19)

🔄CTP-543Sun PharmaceuticalPhase 3

🔄Deuruxolitinib + PlaceboSun PharmaceuticalPhase 3

✅Baricitinib 4 MG Oral TabletEli LillyApproved

🔄Baricitinib + PlaceboEli LillyPhase 3

🔄minoxidilJohnson & JohnsonPhase 3

🔄5% Minoxidil + 2% MinoxidilJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01724580	Pre-clinical	Completed	—	—	Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
NCT06797310	Phase 2	Recruiting	Jan 23, 2025	Dec 31, 2026	Alopecia Areata
NCT05074420	Phase 3	Terminated	Dec 21, 2021	Nov 4, 2024	Covid19
NCT04517253	Phase 2/3	Terminated	Oct 27, 2020	Nov 28, 2024	Nakajo-Nishimura Syndrome
NCT03921554	Phase 2	Completed	Jun 3, 2019	Mar 25, 2024	Aicardi Goutieres Syndrome
NCT03773965	Phase 3	Recruiting	Apr 5, 2019	Jul 1, 2031	Juvenile Idiopathic Arthritis
NCT03559270	Phase 3	Terminated	Jun 27, 2018	Jun 13, 2022	Atopic Dermatitis
NCT03026504	Phase 2	Completed	Mar 9, 2017	Apr 12, 2021	Arteritis, Giant Cell
NCT02263911	Phase 1	Completed	Nov 1, 2014	Dec 1, 2014	Healthy Participants
NCT01870388	Phase 1	Completed	Jun 1, 2013	Jul 1, 2013	Liver Diseases

Competing Products

20 competing products in Alopecia Areata

See all competitors

Product	Company	Stage	Hype Score
CTP-543	Sun Pharmaceutical	Phase 2/3	42
CTP-543	Sun Pharmaceutical	Phase 3	40
Deuruxolitinib + Placebo	Sun Pharmaceutical	Phase 3	47
Baricitinib + Placebo	Eli Lilly	Phase 2/3	38
Baricitinib 4 MG Oral Tablet	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	47
Baricitinib + Placebo	Eli Lilly	Phase 3	40
minoxidil	Johnson & Johnson	Phase 3	40
5% Minoxidil + 2% Minoxidil	Johnson & Johnson	Phase 3	40
Minoxidil + vehicle of 5% Minoxidil topical foam	Johnson & Johnson	Phase 2	35
5% Minoxidil Topical Foam + Vehicle Topical Foam	Johnson & Johnson	Phase 3	40
Upadacitinib + Upadacitinib Placebo	AbbVie	Phase 3	47
Upadacitinib + Placebo	AbbVie	Phase 3	47
Secukinumab + Placebo	Novartis	Phase 2	27
Daxdilimab	Amgen	Phase 2	35
Ritlecitinib	Pfizer	Pre-clinical	30
LITFULO	Pfizer	Pre-clinical	30
Ritlecitinib	Pfizer	Pre-clinical	33
Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo	Pfizer	Phase 3	47
Ritlecitinib	Pfizer	Pre-clinical	26